• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Natera Inc (NQ: NTRA )

    92.88 -1.16 (-1.23%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 621,739
    Open 93.06
    Bid (Size) 90.19 (1)
    Ask (Size) 99.00 (5)
    Prev. Close 94.04
    Today's Range 92.10 - 94.96
    52wk Range 36.90 - 98.82
    Shares Outstanding 120,757,877
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Looking Into Natera's Recent Short Interest
    Via Benzinga
    Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
    From Natera, Inc.
    Via Business Wire

    Performance

    YTD
    +50.00%
    +50.00%
    1 Month
    -0.09%
    -0.09%
    3 Month
    +39.86%
    +39.86%
    6 Month
    +147.35%
    +147.35%
    1 Year
    +76.98%
    +76.98%

    More News

    Read More
    Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
    From Natera, Inc.
    Via Business Wire
    Cracking The Code: Understanding Analyst Reviews For Natera
    Via Benzinga
    Looking Into Natera's Recent Short Interest
    Via Benzinga
    Natera Inc. (NASDAQ: NTRA) Records 52-Week High Friday Morning
    Via Investor Brand Network
    Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
    From Natera, Inc.
    Via Business Wire
    Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
    From Natera, Inc.
    Via Business Wire
    Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
    From Natera, Inc.
    Via Business Wire
    Recap: Natera Q4 Earnings
    Via Benzinga
    Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
    From Natera, Inc.
    Via Business Wire
    New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
    From Natera, Inc.
    Via Business Wire
    Disney, Natera, Chubb And A Major Tech Stock On CNBC's 'Final Trades'
    Via Benzinga
    Earnings Preview For Natera
    Via Benzinga
    Natera to Present New Data at the 2024 SGO Annual Meeting on Women’s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
    From Natera, Inc.
    Via Business Wire
    9 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
    From Natera, Inc.
    Via Business Wire
    Agilent Technologies Stock Getting Closer To Key Technical Benchmark
    Via Investor's Business Daily
    Wall Street Takes A Breather As Inflation Stays Tamed, AMD Hits Record Highs, Apple Struggles: What's Driving Markets Thursday?
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Natera to Participate in March Investor Conferences
    From Natera, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Natera Reports Fourth Quarter and Full Year 2023 Financial Results
    From Natera, Inc.
    Via Business Wire
    Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
    Via Benzinga
    Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
    From Natera, Inc.
    Via Business Wire
    Earnings Scheduled For February 28, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.